FDA Warning Letter to Vacation, Inc. (Aug 6, 2025): What Happened, Why It Matters, and What Comes Next

On August 6, 2025, the FDA issued a Warning Letter to Vacation, Inc. over its “Classic Whip” sunscreens sold in mousse/whipped-cream style canisters. The agency says these products are misbranded and illegally marketed because the foam dosage form isn’t permitted under today’s OTC sunscreen rules—and because the packaging closely resembles edible whipped cream, creating a risk of accidental ingestion. U.S. Food and Drug Administration

The short version

Products cited: Classic Whip Broad Spectrum SPF 30 Sunscreen Mousse and Classic Whip Glow Broad Spectrum SPF 30 Shimmer Sunscreen Mousse. U.S. Food and Drug Administration
Core issues:
1. Dosage form: “Foam/mousse/whip” isn’t among the FDA’s allowable OTC sunscreen forms (oil, lotion, cream, gel, butter, paste, ointment, stick, spray, powder). Without a specific FDA order authorizing foam, a product in that form must have an approved NDA/ANDA—these do not. U.S. Food and Drug Administration
2. Packaging: The canisters and actuator strongly resemble food-grade whipped cream containers, which FDA says can mislead consumers (including children) and raise ingestion risks—another ground for misbranding. U.S. Food and Drug Administration
Timeline: FDA reviewed labeling and social posts on March 5, 2025; the letter was issued August 6, 2025; the firm has 15 working days to respond. U.S. Food and Drug Administration

Why the dosage form matters (the 505G / monograph angle)

Sunscreens marketed without individual FDA approval have to fit within the final OTC sunscreen monograph order (M020) under section 505G of the FD&C Act. That monograph recognizes specific dosage forms. Foam/mousse/whip is not one of them. Under 505G(m)(2), dosage forms that weren’t eligible under the old OTC review can’t be marketed without an approved application unless FDA issues a specific order authorizing them—which it has not done for sunscreens in foam/mousse/whip form. Therefore, even if Vacation’s formulas met SPF/labeling conditions, the dosage form alone keeps them out of compliance, rendering them misbranded under section 502(ee). U.S. Food and Drug Administration

The letter also notes that “foam” is the technical dosage-form term in USP <1151>, whereas “mousse” and “whip” aren’t established dosage-form names—underscoring FDA’s view that these are non-monograph forms. U.S. Food and Drug Administration

The packaging problem

Vacation markets Classic Whip in metal canisters with a “tilt-valve” actuator that dispenses star-shaped dollops, intentionally mimicking dessert toppings (the company’s marketing has called it “dessert for your skin”). FDA says the look-alike to food packaging can mislead consumers and heighten the risk of accidental ingestion, particularly for children—triggering misbranding under section 502(i)(1) (“container … made, formed, or filled as to be misleading”). The letter even references a supplier’s page highlighting collaboration to emulate Reddi-wip®-style packaging. U.S. Food and Drug Administration

Exactly what FDA cites Vacation for

Marketing an OTC sunscreen in a non-authorized dosage form (foam/mousse/whip) without an approved application or an FDA order authorizing that dosage form (violation of 505G; 502(ee) misbranding). U.S. Food and Drug Administration
Misleading container/packaging that resembles food canisters, creating safety risks (misbranding under 502(i)(1)). U.S. Food and Drug Administration

FDA also lays out typical Warning Letter expectations: respond within 15 working days describing corrective steps, with documentation; failure can lead to seizure and injunction. U.S. Food and Drug Administration

How we got here (broader industry context)

This action is part of a coordinated set of letters in early August 2025 aimed at mousse/foam/whipped sunscreens sold by several brands; FDA also highlighted potential effectiveness concerns for mousse sunscreens in public statements and media briefings. Independent reporting notes that while ingredients may be similar to monograph lotions or sprays, the format itself is the sticking point under current U.S. rules. Some brands have indicated they’ll cooperate and review changes. Allure The Cut

What this means—for brands, retailers, and consumers

For brands & formulators

Form matters as much as formula. If your sunscreen isn’t one of the permitted monograph dosage forms, you need either a final FDA order authorizing it or an approved NDA/ANDA. Absent that, it’s misbranded even if SPF testing is solid. U.S. Food and Drug Administration
Beware look-alike packaging. If your drug container resembles food or drink, FDA may consider it misleading (502(i)(1)). Conduct “look-alike” risk assessments—especially for child-attracting designs. U.S. Food and Drug Administration
Audit claims and social media. FDA cited Vacation’s website and Instagram as labeling that evidences intended use. Treat owned media and posts as labeling for compliance purposes. U.S. Food and Drug Administration

For retailers

Expect stock reviews and possible voluntary holds/pulls on mousse/whip sunscreens pending companies’ responses. Retailers should request corrective action letters and updated product status from suppliers. (Context from broad reporting on the coordinated letters.) Allure The Cut

For consumers

FDA’s letters focus on regulatory compliance and potential effectiveness/ingestion risks tied to mousse formats and food-like packaging—not necessarily on an immediate safety defect in the active ingredients. The safest course is to use FDA-compliant dosage forms (lotions, sticks, sprays, etc.) per label directions. (Media summaries of FDA public messages.) CBS News

Practical compliance checklist (OTC sunscreen, U.S. market)

Confirm dosage form is one of: oil, lotion, cream, gel, butter, paste, ointment, stick, spray, or powder. Anything else (e.g., foam/mousse/whip) requires a specific FDA order or an approved application. U.S. Food and Drug Administration
Align to M020 (current sunscreen monograph order) for actives, testing, SPF/“broad spectrum” claims, and 21 CFR 201.327 labeling elements. U.S. Food and Drug Administration
Container/closure risk review: avoid look-alike food/beverage designs; document human factors and child safety considerations (to mitigate 502(i)(1) risk). U.S. Food and Drug Administration
End-to-end labeling control: websites, influencers, and brand social posts are “labeling” if they promote the drug product; implement pre-clear and monitoring. U.S. Food and Drug Administration
Rapid WL response plan: designate owners for root cause, corrective actions, market status decisions (hold/recall/repack), and regulatory interactions; reply within 15 working days with evidence. U.S. Food and Drug Administration

Likely paths forward for Vacation, Inc.

Cease U.S. sales of the mousse format or reformulate/repackage into a permitted dosage form (e.g., lotion or spray) aligned to M020. U.S. Food and Drug Administration
Repackage away from a whipped-cream aesthetic to address 502(i)(1). U.S. Food and Drug Administration
Pursue a formal application (e.g., NDA) if the company aims to keep a foam dosage form—a lengthy, data-heavy route because efficacy, performance, and safety in that format would need to be demonstrated. (Inference from 505G framework and lack of a foam authorization.) U.S. Food and Drug Administration

Key dates & documents at a glance

Mar 5, 2025: FDA reviews Vacation’s labeling and social promotions. U.S. Food and Drug Administration
Aug 6, 2025: Warning Letter issued (MARCS-CMS 706039). U.S. Food and Drug Administration
Aug 12, 2025: FDA page notes “Content current as of” this date. U.S. Food and Drug Administration
Response window: 15 working days from receipt. U.S. Food and Drug Administration

Sources & further reading

Primary source: FDA Warning Letter to Vacation, Inc. (MARCS-CMS 706039), including the statutory citations (505G; 502(ee); 502(i)(1)), product identification, packaging analysis, and response instructions. U.S. Food and Drug Administration
Industry context & reporting: Allure, The Cut, and other outlets summarize FDA’s coordinated letters to mousse/foam sunscreens and the agency’s public messaging around effectiveness and ingestion risk tied to packaging that looks like food. Allure The Cut

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.